ArticleResearch square2025
Correlations of CSF Biomarkers of Alzheimer's Disease with Cognitive Measures in MCI and AD Dementia: A Cross-Sectional Analysis.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background and Objectives: We examined the relationships between cerebrospinal fluid (CSF) amyloid-β, tau, p-tau, and cognition in an Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Studies have examined the longitudinal relationships between CSF biomarkers for Alzheimer's disease (AD) and cognition, but there is discordance in the strength of associations between CSF amyloid-β, t-tau, or p-tau with cognition at different disease stages. Methods: The study included 665 patients from the combined ADNI dataset: 128 cognitively normal (CN), 175 with mild cognitive impairment (MCI), and 362 with AD dementia. All patients were amyloid-β-positive according to established CSF amyloid-β cut-off values. Cognitive assessments, diagnoses, and specimen collection/processing were conducted via published standardized protocols. We examined cross-sectional baseline data and performed correlational and regression analyses to evaluate the associations between CSF biomarkers and assessments of learning, memory, executive function, language, attention, visuospatial skills, and activities of daily living. Results: In the MCI cohort, significant negative correlations were observed between CSF amyloid-β and ADAS-Cog11 (r=-0.164, p=0.02, ADAS-Cog13 (r=-0.181, p=0.01), Trails B (r=0.11, p=0.04), and FAQ (r=-0.131, p=0.01). There were positive correlations between amyloid-β and MMSE (r=0.149, p=0.004) and amyloid-β and WMS-delayed recall (r=0.116, p=0.03). Statistically significant correlations were observed between CSF t-tau and p-tau and CDRSB (t-tau: r=0.105, p=0.047), ADAS-Cog11 (t-tau: r=0.114, p=0.03; p-tau-181: r=0.114, p=0.03), ADAS-Cog13 (t-tau: r=0.165, p=0.002; p-tau-181: r=0.162, p=0.002), RAVLT-forgetting (t-tau: r=0.173, p=0.001; p-tau-181: r=0.167, p=0.001), and WMS-delayed recall (t-tau: r=-0.237, p<0.001 and p-tau-181: r=-0.235, p<0.001). In the AD cohort, no statistically significant relationships were observed between CSF amyloid-β Discussion: The findings suggest that the relationship between CSF biomarkers and cognitive performance is strongest in MCI. The lack of significant correlations in the AD cohort may indicate other pathophysiological changes dominating cognitive dysfunction at this disease stage. Both tau and amyloid showed similar utility in reflecting cognitive impairment, in contrast to some reports in the literature. Further research is warranted to explore biomarker longitudinal impacts and their predictive values across the spectrum of cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.